1. Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies
2. Juweid, M. E., Stadtmauer, E., Hajjar, G., Sharkey, R. M., Suleiman, S., Luger, S., Swayne, L. C., Alavi, A., and Goldenberg, D. M. (1999) Pharmacokinetics, dosimetry and initial therapeutic results with131I- and111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).Clin. Cancer Res.5, 3292s−3303s.
3. DeNardo, S. J., DeNardo, G. L., Yuan, A., Richman, C. M., O'Donnell, R. T., Lara, P. N., Kukis, D. L., Natarajan, A., Lamborn, K. R., Jacobs, F., and Siantar, C. L. (2003) Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N‘,N‘ ‘,N‘ ‘‘-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.Clin. Cancer Res. 9, 3938s−3944s.